ANTIBACTERIAL POTENTIAL OF MANUKA HONEY AGAINST EXTENDED SPECTRUM BETA LACTAMASES PRODUCING CLINICAL ISOLATES

Abstract

Infectious diseases induced by drug-resistant bacteria are one of the major problems in clinical practice. In the ongoing scenario, where the resistant bacteria are spreading widely and limited options for treatment are presently available with antimicrobial agents. The study was conducted to determine antibacterial potential of Manuka honey (MH)BV20+ joint at different strength against extended spectrum beta lactamases (esbl) producing bacteria including Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumonia (n = 30 for all isolates). Resistance pattern along with minimum inhibitory concentrations (MIC) and minimum bactericidal concentrations (MBC) were analysed. From thirty clinical isolates each of Escherichia coli, Pseudomonas aeruginosa and Klebsiella pneumoniae, no one showed resistance against manuka honey even at 4000 $\mu$L/mL dilution but twelve samples of Escherichia coli and ten samples of Klebsiella pneumonia showed resistance against Ciprofloxacin, used as positive control. The average zone of inhibition of Ciprofloxacin against Escherichia coli was 24.14 mm, for Pseudomonas aeruginosa it was 26.38 mm and 25.14 mm for Klebsiella pneumoniae while the average zone of inhibition of undiluted manuka honey against Escherichia coli was 29.38 mm, for Pseudomonas aeruginosa it was 28.22 mm and 25.21 mm for Klebsiella pneumoniae. MIC and MBC were found to be 4000 $\mu$L/mL against Escherichia coli and Pseudomonas aeruginosa while for Klebsiella pneumonia it was 5000 $\mu$L/mL. Manuka honey BV20+ joint showed an excellent antibacterial potential against resistant strains of extended spectrum beta lactamases bacteria indicating its significance in clinical practice.